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Cryptogenic stroke has been a challenge for years in clinical practice, given it can represent
up to 40% of strokes, depending on the etiological classification used, which has different
operative definitions for those patients in whom the complete diagnostic workup does not reveal
a specific stroke etiology. In 2014, two opposing approaches to the challenge of cryptogenic
stroke were proposed. On the one hand, Bang et al. proposed its assessment using advanced
diagnostic techniques (such as advanced vascular imaging and cardiac monitoring, aortogenic, and
paradoxical embolic source assessment, coagulopathy, and cancer screening tests) as a measure
to reduce the proportion of cryptogenic strokes by increasing the diagnosis of atheroembolic
disease, aortic embolic disease, branch occlusive disease, paroxysmal atrial fibrillation, paradoxical
embolism, and cancer-related coagulopathy (1). On the other hand, the Cryptogenic Stroke/ESUS
International Working Group proposed a new clinical construct that they named embolic stroke of
undetermined source (ESUS) (2). The rationale behind the ESUS concept was the assumption that
most cryptogenic strokes were thromboembolic and could benefit from non-vitamin K agonist
oral anticoagulants (NOACs) that had already demonstrated their efficacy and safety in atrial
fibrillation (AF), to reduce recurrent brain ischemia. This suggestion prompted the development of
randomized clinical trials testing the safety and efficacy of rivaroxaban and dabigatran in patients
with ESUS as well as the rapid dissemination of the ESUS concept to clinical practice due to the
simplicity of the diagnostic workup, which required only the demonstration by neuroimaging
procedures [computed tomography (CT) or magnetic resonance imaging (MRI)] of a non-lacunar
infarction, the absence of extracranial or intracranial atherosclerosis causing≥50% luminal stenosis
in arteries supplying the ischemic area, no major-risk cardioembolic source of embolism and no
other cause of stroke identified. The only diagnostic procedure assessments required were brain
CT or MRI, 12-lead electrocardiogram (ECG), precordial echocardiography, cardiac monitoring
for ≥24 h with automated rhythm detection and imaging of extracranial and intracranial arteries
by either ultrasonography or MRI, CT, or catheter angiography.
However, the failure of the RESPECT-ESUS andNAVIGATE-ESUS trials (3, 4) in demonstrating
any efficacy in the prevention of stroke recurrences in patients with ESUS has called into question
the practical usefulness of this concept as, compared with the concept of cryptogenic stroke,
the only difference is the exclusion of lacunar stroke (5–9). Therefore, ESUS remains a non-
diagnosis similar to the classic cryptogenic stroke concept. Some of the most commonly used stroke
classifications, such as the TOAST (10) and the ESUS criteria themselves (2), were developed for
use in clinical trials; however, they have been incorporated in clinical practice without enough
validation studies to truly evaluate their usefulness in clinical settings. Stroke physicians attend
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stroke patients daily in whom there is no clear evidence
of the underlying etiology and must choose between two
options. One is to make the diagnosis of ESUS (which is
not actually associated with any specific therapeutic change),
and the other is to make a greater effort to identify the
ultimate cause of the stroke by the use of advanced diagnostic
techniques (1). Choosing one or the other option is crucial
for secondary stroke prevention, given the treatments can
be different.
In this opinion article, we would like to highlight some
of the arguments against the use of the ESUS concept in
clinical practice:
• The rationale behind the ESUS concept, considering that
many ESUSs would be due to covert paroxysmal AF,
and therefore would benefit from the use of NOAC, has
clearly failed, not only because of the neutral/negative
results of the RESPECT-ESUS and NAVIGATE-ESUS trials
(3, 4), but also because clinical trials with long-term
ECG monitoring as well as observational studies have
shown that covert AF represents only about 30% of
ESUS (11–13).
This low rate of AF detection during follow-up, the different
phenotypes between patients with ESUS and patients with
stroke with AF, and data from studies with implantable cardiac
monitoring devices showing that the majority of embolic
events do not occur proximal to episodes of AF have raised
doubts regarding the causal association between covert AF and
ESUS (14).
• The authors of the ESUS construct acknowledged that
arteriogenic embolism due to non-stenotic plaques was
possible in some patients with ESUS (2). However,
grouping them into the same category as patients with
other minor cardioembolic strokes, assuming that they
would also benefit from anticoagulants, risks neglecting
the atherothrombotic origin in patients with stroke with
carotid atherosclerosis with stenosis lower than 50% or with
aortic arch atheroma (AAA); these etiologies require a more
tailored approach to atherosclerosis to prevent not only
stroke recurrences, but also other vascular events such as
myocardial infarction.
Several studies have reported a higher prevalence of ipsilateral
carotid plaques than contralateral carotid plaques in some
ESUS cohorts (15, 16), and the global prevalence of carotid
non-stenotic plaques in the ESUS Global Registry is as high as
79% (17). Recently published data from the NAVIGATE trial
have shown that up to 40% of the patients included in that trial
had carotid plaques, this being clearly more frequent on the
ipsilateral side to the qualifying stroke. Interestingly, the group
of patients with carotid plaques showed a strong tendency to
higher frequency of stroke recurrences compared with those
without carotid plaques (18).
Similarly, AAA is a frequent finding in patients with
ESUS (when screened), found in up to 28% in the ESUS
Global registry (17) and in the 29% of patients who had
transesophageal echocardiography (TEE) included in the
NAVIGATE trial, and they showed a higher frequency of
multiterritorial infarcts in neuroimaging (19). Therefore, for
cases in which the stroke physician follows the ESUS criteria,
which does not require TEE, many symptomatic AAA cases
might be missed. Although clinical trials on the use of
antithrombotic drugs in stroke prevention in AAA were
inconclusive because of insufficient power calculation (19–
21), these patients carry a higher risk of stroke recurrences
than patients with other possible causes of cryptogenic stroke
(20) and have a high burden of vascular risk factors and of
coronary artery disease (19–21). Therefore, they should be
instructed to strictly adhere to lifestyle modifications and risk
factor interventions to reduce the overall vascular risk, instead
of providing them with the uncertainty of an ESUS diagnosis.
• Patent foramen ovale (PFO) has also been included in
the broad concept of ESUS (2), following the historical
controversy on its pathogenic role in ischemic stroke. It
has been reported to be present in up to 7.4% of patients
with ESUS recruited in the NAVIGATE trial (22) and in
12.6% in the RESPECT-ESUS trial (3); however, actual rates
could be underestimated, given TEE, or bubble transcranial
Doppler were not required prior to inclusion in the trials.
None of them showed NOAC to have any significant effect
on reducing stroke recurrences. Moreover, given percutaneous
PFO closure has been demonstrated to be safe and efficacious
in the prevention of stroke recurrences in those patients
with ischemic stroke related to large PFOs (especially when
associated with atrial septal aneurysm) and no other cause
of stroke (23, 24), they should be excluded from the ESUS
category because the therapeutic approach is clearly different.
Indeed, an update of current nomenclature and classifications
systems has recently been proposed to include the specific
category of PFO-associated stroke (25).
• Cancer-associated stroke is another possible underlying
etiology in patients with ESUS (2) and data from the
NAVIGATE trial reported a cancer diagnosis in up to
7.5% of the included patients. This value is probably
an underestimate, given an exclusion criterion was a life
expectancy of <6 months. A new cancer diagnosis at
11 months’ follow-up was found in 1.7% (26). Patients
with cancer had a higher risk of stroke recurrences than
patients without cancer, without differences in ischemic stroke
recurrences between the aspirin and rivaroxaban groups,
although with a trend toward more major bleeds with
rivaroxaban (26). Involved pathogenic mechanisms are non-
bacterial thrombotic endocarditis, tumor emboli from occult
cancer and a cancer-associated hypercoagulable state. Cancer-
associated stroke has a very poor prognosis, with high
mortality at follow-up (27, 28). Identifying and treating the
underlying cancer is crucial in these patients. For this reason,
following such a basic diagnostic approach as required for
ESUS appears to be inappropriate for the detection of stroke-
associated cancer and, in our opinion, further laboratory tests
(such as D-dimer, which has been proposed as a helpful
parameter for suspected covert cancer in stroke patients) (29)
and cardiac examinations (such as TEE to rule out non-
bacterial thrombotic endocarditis) should be performed.
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FIGURE 1 | A proposal for stroke of unknown etiology, cryptogenic stroke classification and diagnostic approach. CT, Computed Tomography; DVT, Deep Venous
Thrombosis; ECG, Electrocardiogram; MRI, Magnetic Resonance Imaging; PET/CT, Positron Emission Tomography/Computed Tomography; TCD, Transcranial
Doppler; TEE, Transesophageal Echocardiography.
• Finally, there are some other less recognized cardioembolic
sources of stroke, such as atrial cardiopathy and left
ventricular disease, including hypertrophy, decreased ejection
fraction and valvular heart disease without AF, which merit
identification in patients with stroke. The results of the
ongoing ATTICUS and ARCADIA trials (30, 31) that are
investigating the efficacy and safety of apixaban in patients
with disease of unknown etiology and atrial cardiopathy or
at least one risk factor suggestive of cardiac embolism should
provide us with new insights into the role of atrial cardiopathy
and the risk of stroke, whether mediated or not by covert
AF. These trials are selecting cryptogenic stroke patients who
present the following markers suggestive of atrial cardiopathy:
left atrium enlargement >45mm, spontaneous echo contrast
in left atrial appendage (LAA), LAA flow velocity ≤0.2 m/sg,
atrial high rate episodes, PFO and high CHADS2-VASc score
(≥4) in the ATTICUS Trial; and the P-wave terminal force
> 5,000 µV x ms in ECG lead V1, serum N-terminal pro-
brain natriuretic peptide (NT-ProBNP) >250 pg/ml, and
left atrial diameter index ≥3 cm/m2 in the ARCADIA
Trial (30, 31).
Therefore, in our opinion, the exclusion of ipsilateral non-
stenotic carotid plaques, aortic arch atherosclerosis, PFO,
and cancer-associated strokes should be a prerequisite before
diagnosing a cryptogenic stroke in clinical practice (Figure 1),
and patients with factors that have been identified as being
associated with a higher risk of covert AF should undergo long-
term cardiac monitoring. In this sense, the evaluation of serum
(Nt-ProBNP) could help in the selection of patients for long-term
cardiac monitoring since levels ≥505 pg/ml have recently shown
to have a 86% sensitivity and 98% negative predictive value for
AF in cryptogenic stroke (32).
In conclusion, our advice to stroke physicians is to forget
ESUS and be smart in the search for underlying causes of
ischemic stroke, optimizing advanced diagnostic procedures
according to the patient’s and stroke’s characteristics, attempting
to find the correct diagnosis for stroke patients and reducing rates
of cryptogenic stroke diagnosis.
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